Komori
A

ASKA Pharmaceutical Holdings Co.,Ltd.

4886PharmaceuticalsSmall cap
2,011JPY-2.2%
★ Watch (sign-up required)
Price history
¥2,011Latest+109.0%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

Based on its founding philosophy, the Group operates healthcare-related businesses centered on its core prescription pharmaceuticals business, including animal health, overseas operations and testing. Its core business is the domestic prescription pharmaceuticals business, and the Group is pursuing global expansion, primarily in Asia, by strengthening its specialty areas, including obstetrics and gynecology. In addition, it aims to achieve long-term growth and help address social issues by strengthening its drug discovery platform, including drug discovery and licensing-in and licensing-out activities, establishing production and supply systems at its overseas sites, and expanding its testing and medical device-related businesses. The Group aims to enhance corporate value by advancing sustainability management, strengthening the use of digital technologies and reinforcing governance.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
108.25How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.75How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
0.7%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥58bnShare price × number of shares. The value of the entire company.
Equity ratio
64.4%The proportion of assets funded by money that does not have to be repaid.
Operating margin
4.1%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
2.8%The average annual growth in sales over the past three years.
What to watch next
Ha Tay new plant: completion of the investment plan (scheduled for December 2026) and start of commercial production (scheduled for 2026)
From 2026 through 2027Impact HighLikelihood Medium
Core products: continued monitoring of the revenue growth rates of Relmina (uterine fibroids/endometriosis) and Dro-Eti (planned ongoing sales)
Continued confirmation over the coming quarters and full fiscal yearsImpact MediumLikelihood High
LF111 (a drospirenone-based contraceptive): progress in preparations for launch following domestic approval, including confirmation of the launch start and initial sales
From the first half of fiscal 2026 onward (the launch timing disclosed by the company requires confirmation)Impact MediumLikelihood Medium
Pipeline: progress of AKP-022 (a relugolix combination product) through Phase III in endometriosis, for which the start timing has been disclosed, and disclosure of the results
Timing of Phase III results disclosure (undetermined)Impact HighLikelihood Low
Drug price revisions and medical finance: changes in demand and unit prices resulting from regulatory changes
Dependent on the institutional revision cycle; continued monitoring throughout the fiscal yearImpact HighLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 50.4%
Listed holders 50.4%Everyone else 49.6%
The Master Trust Bank of Japan, Ltd. (Trust Account)9.40%
NIPPON ACTIVE VALUE FUND PLC (Permanent representative: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)8.44%
Takeda Pharmaceutical Company Limited7.76%
ZERIA PHARMACEUTICAL CO.,LTD.6.61%
STATE STREET BANK AND TRUST COMPANY 505103（常任代理人：みずほ銀行）4.00%
MUFG Bank, Ltd.3.87%
NAVF SELECT LLC（常任代理人：香港上海銀行東京支店）2.98%
NOMURA PB NOMINEES LIMITED OMNIBUS MARGIN（CASHPB）（常任代理人：野村證券株式会社）2.78%
2 other listed holders4.57%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)9.40
NIPPON ACTIVE VALUE FUND PLC (Permanent representative: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)8.44
Takeda Pharmaceutical Company Limited7.76
ZERIA PHARMACEUTICAL CO.,LTD.6.61
STATE STREET BANK AND TRUST COMPANY 505103（常任代理人：みずほ銀行）4.00
MUFG Bank, Ltd.3.87
NAVF SELECT LLC（常任代理人：香港上海銀行東京支店）2.98
NOMURA PB NOMINEES LIMITED OMNIBUS MARGIN（CASHPB）（常任代理人：野村證券株式会社）2.78
2 other listed holders4.57
This company's documents
Filings
Timely disclosures
Threads